Pharmafile Logo
Pharmafocus logo
Advanced Search

Biogen

Showing 15 posts of 117 posts found.

Biogen’s high-dose Spinraza regimen receives European Commission approval for spinal muscular atrophy

January 19, 2026
Research and Development Biogen, Neurology, Spinraza, spinal muscular atrophy

Biogen’s Spinraza (nusinersen) has received approval from the European Commission (EC) as a new high-dose regimen for the treatment of …

News
trial

Biogen and Stoke report positive results for Dravet syndrome drug

July 17, 2025
Research and Development Biogen, Dravet Syndrome, Neurology, Stoke Therapeutics, epilepsy, rare diseases

Biogen and Stoke Therapeutics have shared encouraging new data for their experimental treatment, zorevunersen, which is being developed for Dravet …

News
robina-weermeijer-so1l3jsdd3y-unsplash_2

Eisai and Biogen’s Leqembi launched for Alzheimer’s treatment in China

June 28, 2024
Business Services Alzheimers, Biogen, Eisai, Leqembi, Neurology, lecanemab

Eisai and Biogen have announced that Leqembi (lecanemab) has been launched in China as a treatment for mild cognitive impairment …

News
robina-weermeijer-ihfopazzjhm-unsplash_5

FDA accepts Eisai’s Leqembi sBLA for early AD treatment

June 11, 2024
Medical Communications Alzheimer's, Biogen, FDA, Neurology, sBLA

Eisai and Biogen have announced that the US Food and Drug Administration (FDA) has accepted Eisai’s supplemental biologics license application …

News

BioGen to acquire Human Immunology Biosciences for $1.15bn

May 23, 2024
Business Services Biogen, HI-Bio, Immunology, acquisition, immunology

BioGen and Human Immunology Biosciences (HI-Bio) have announced that they have entered into a definitive agreement for Biogen to acquire …

News
robina-weermeijer-so1l3jsdd3y-unsplash_2

Eisai shares new data for Leqembi for Alzheimer’s treatment

October 26, 2023
Research and Development Alzheimer's, Biogen, Eisai, Neurology, lecanemab

Eisai and Biogen have announced that Eisai has shared new data for Leqembi (lecanemab-irmb) 100mg/mL injection for intravenous (IV) use …

News

Biogen’s biosimilar Tofidence approved by FDA

October 2, 2023
Medical Communications Actemra, Biogen, FDA, Musculo-skeletal disorder, Tofidence

Biogen has announced that the US Food and Drug Administration (FDA) has approved Tofidence (tocilizumab-bavi) as an intravenous formulation, a …

News
money_pills_2

Biogen to acquire Reata Pharmaceuticals

July 31, 2023
Business Services Biogen, Neurology, Reata Pharmaceuticals, acquisition

Biogen and Reata Pharmaceuticals have announced that they have entered a definitive agreement under which Biogen will acquire Reata for …

News
Alzheimer's brain

FDA grants Alzheimer’s disease drug Leqembi full approval

July 7, 2023
Medical Communications Alzheimer's disease, Biogen, Eisai, FDA, Neurology

Japanese pharmaceutical company Eisai and US-based biotechnology company Biogen have announced that the US Food and Drug Administration (FDA) has …

News

Biogen Phase III choroideremia study did not meet primary endpoint

June 15, 2021
Manufacturing and Production Biogen, choroideremia, phase III

Biogen has announced that its investigational gene therapy study for the potential treatment of choroideremia did not meet its primary …

News
biogen_austria_238

Biogen fails to meet primary endpoint in XLRP study

May 17, 2021
Sales and Marketing Biogen, Clinical Trail

Biogen have released topline results from its Phase2/3 Xirius study of cotoretigene toliparvovec (BIIB112) as a gene therapy for patients …

News
dw-anzcxqaqavhl

FDA approves new IM administration route for Biogen’s MS drug Plegridy

February 2, 2021
Manufacturing and Production Biogen, MS

The FDA has approved a new intramuscular (IM) injection route of administration for Biogen’s Plegridy (peginterferon beta-1a) for the treatment …

News
boehringer_biberach_germany_copy

Researchers and pharma companies partner to investigate new schizophrenia treatment

January 21, 2021
Biogen, Boehringer Ingelheim

The University of Oxford, the Earlham Institute, and global pharmaceutical companies Biogen and Boehringer Ingelheim are partnering to investigate a …

News
european_commission_web

Biogen’s IM Plegridy gets EU approval

January 6, 2021
Research and Development Biogen, multiple sclerosis

The European Commission has approved Biogen’s Plegridy (peginterferon beta-1a), a new intramuscular (IM) injection for the treatment of relapsing-remitting multiple …

News
biogen

Biogen agrees to pay $22m to settle kickback allegations

December 18, 2020
Medical Communications Biogen, multiple sclerosis

Biogen has agreed to pay $22 million to put an end to an investigation into claims that it illegally used …

News
The Gateway to Local Adoption Series

Latest content

Historic UN declaration supporting mental health – treatment to be given similar priority to chronic diseases

January 30, 2026

Rare diseases – spinal muscular atrophy

January 30, 2026

Could targeting the molecular causes of infertility finally transform IVF success rates?

January 29, 2026

Digital mental health technologies – a valuable tool in supporting people with depression and anxiety

January 29, 2026

Barts Health NHS Trust collaborates with H.I.G. Realty on healthcare innovation building

January 29, 2026